// App-Quantinova.ai

2965 : AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Researchers

Presenter

  • Matthew J Ahearne

Principal Investigators

  • Charlotte Gaskell

  • Aimee E Jackson

  • Clare Morland

  • Louise Hopkins

  • Nadia Nawaz

  • Matthew A Timmins

  • Christopher P Fox

  • Graham P. Collins

  • Andrew Davies

  • David John Lewis

  • Kate Cwynarski

  • Kim Linton

  • Pam McKay

  • Rod Johnson

  • Simon D. Wagner

Medical Centers

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom

  • University of Leeds, Leeds, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Plymouth Hospitals NHS Trust - Derriford Hospital ,Plymouth,United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • The Christie Hospital, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • St James Hospital, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Acetaminophen

  • Avelumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved